Ki-67 expression in operable breast cancer: A comparative study of immunostaining and a real-time RT-PCR assay

Potemski, Piotr; Płuciennik, Elżbieta; Kusińska, Renata; Kubiak, Robert; Jesionek-Kupnicka, Dorota; Watała, Cezary; Kordek, Radzisław

doi:10.1016/j.prp.2006.02.005

Cited by 20 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may indicate that stromal expression of TGF-β is particularly important in the early stage of tumor progression. Proliferative activity defined by Ki67 staining is associated with cancer progression and poor prognosis in a number of malignant tumors, including breast cancer [49]. Our study is in line with these reports, showing the highest expression of Ki67 in stroma of the metastases.…”

Section: Discussionsupporting

confidence: 91%

Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer

et al. 2012

View full text Add to dashboard Cite

BackgroundThe immune system has paradoxical roles during cancer development and the prognostic significance of immune modulating factors is controversial. The aim of this study was to determine the expression of cyclooxygenase 2 (COX-2), transforming growth factor-beta (TGF- beta), interleukin-10 (IL-10) and their prognostic significance in breast cancers. Ki67 was included as a measure of growth fraction of tumor cells.MethodsOn immunohistochemical stained slides from 38 breast cancer patients, we performed digital video analysis of tumor cell areas and adjacent tumor stromal areas from the primary tumors and their corresponding lymph node metastases. COX-2 was recorded as graded staining intensity.ResultsThe expression of TGF-beta, IL-10 and Ki67 were recorded in tumor cell areas and adjacent tumor stromal areas. In both primary tumors and metastases, the expression of COX-2 was higher in the tumor stromal areas than in the tumor cell areas (both P < 0.001). High stromal staining intensity in the primary tumors was associated with a 3.9 (95% CI 1.1-14.2) times higher risk of death compared to the low staining group (P = 0.036). The expression of TGF-beta was highest in the tumor cell areas of both primary tumors and metastases (both P < 0.001). High stromal expression of TGF-beta was associated with increased mortality. For IL-10, the stromal expression was highest in the primary tumors (P < 0.001), whereas in the metastases the expression was highest in tumor cell areas (P < 0.001). High IL-10 expression in tumor- and stromal cell areas of primary tumors predicted mortality. Ki67 was higher expressed in tumor stromal areas of the metastases, and in tumor cell areas of the primary tumors (P < 0.001). Ki67 expression in tumor cell areas and stromal areas of the metastases was independently associated with breast cancer mortality.ConclusionsStromal expression of COX-2, TGF-beta and Ki67 may facilitate tumor progression in breast cancer.

show abstract

Section: Discussionsupporting

confidence: 91%

Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The proliferation fraction of the invasive component (i.e. not including ductal carcinoma in situ) of the tumour cells outside lymph vessels (PF-T), was scored using a method similar to that described by Potemski et al and by Rudolph et al [37,38]. First the tumour fields with highest reactivity for MIB-1 were selected and then the number of MIB-1 positive tumour nuclei was counted in 500 tumour cells and this gave the percent of the proliferating tumour cells (500 tumour cells were present in 2-3 high magnification fields, 9400 according to amount of tumoural stroma).…”

Section: Assessment Of Lymphangiogenic and Angiogenic Characteristicsmentioning

confidence: 99%

Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications

Mohammed

Ellis

Elsheikh

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

Controversy exists regarding the topography of lymph vessels in breast cancer, their usefulness as prognostic factors, relationship with angiogenesis and whether active lymphangiogenesis occurs within the tumour. A series of 177 well-characterized breast cancers, with long term follow up, were stained with D2-40, CD31 and CD34. Distribution of lymphatics and lymph vessel density (LVD) were assessed in three areas, intratumoural, peripheral and peritumoural and correlated with clinicopathological criteria and patient prognosis. Microvessel density (MVD) was assessed and correlated with LVD. Double immunohistochemical staining with D2-40 and MIB-1 was carried out to assess the proliferative status of lymphatics and of the tumour emboli within. Peritumoural lymphatics were detected in all tumours whereas peripheral and intratumoural lymphatics were detected in 86 and 41% of specimens, respectively. Tumours with higher total LVD were significantly associated with the presence of lymph node (LN) metastasis and shorter overall survival (OS). In multivariate analysis, tumour grade, LN status and the presence of lymphovascular invasion, but not LVD, were independent poor prognostic factors. No association was found between LVD and MVD. Proliferating lymphatics were detected in 29% of specimens and were significantly associated with dense inflammatory infiltrate. In conclusion, lymphatics are located primarily in the peritumoural and peripheral areas in breast cancer and seem to play an important role in disease progression by being routes for tumour dissemination. The lack of correlation between lymphangiogenic and angiogenic characteristics suggests two distinct processes and the presence of active lymphangiogenesis, albeit in a small portion of specimens, may have important therapeutic implications.Keywords Angiogenesis Á Breast cancer Á D2-40 Á Lymphangiogenesis and prognosis Introduction and aims

show abstract

“…The authors indicated that targeting the mTOR/S6K pathway might be a useful strategy for the treatment of ER+/HER2/neu-breast cancer with high Ki-67 expression. Potemski et al [30] demonstrated that Ki-67 expression levels measured by immunostaining and real-time reverse transcription polymerase chain reaction were weakly concordant, and both were, while not influencing survival, related to higher tumor grade. Our study results support these findings.…”

Section: Discussionmentioning

confidence: 99%

Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer

et al. 2018

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the immunohistochemical expression of ribosomal protein (RP) S6-pS240 in non-special type invasive breast cancer in relation to other prognostic markers and gain new insights to facilitate more individualized treatment. Methods: The following clinical and histopathological parameters of 120 patients were determined: S6-pS240 expression, age, menopausal status, tumor size and grade, TNM stage, Nottingham Prognostic Index (NPI), lymph node stage, estrogen and progesterone receptor (ER/PR) expression, HER2/neu amplification, lymphovascular invasion, and proliferative index as measured by Ki-67. Treatment protocol and disease-free survival were evaluated accordingly. Results: Significant positive correlations were seen between S6-pS240 expression and Ki-67 values (rho = 0.530, p < 0.001), and NPI (rho = 0.370, p < 0.001) and HER2/neu amplification (rho = 0.368, p < 0.001). A negative correlation was found between S6-pS240 and ER/PR expression (rho = 0.362, p < 0.001). Patients with negative RP S6-pS240 expression had significantly longer disease-free survival (log-rank test, p = 0.005). Conclusion: Immunohistochemical analysis of RP S6-pS240 is a valuable additional prognostic marker in patients with invasive breast cancer. Routine use of S6-pS240 immunohistochemistry is recommended.

show abstract

Ki-67 expression in operable breast cancer: A comparative study of immunostaining and a real-time RT-PCR assay

Cited by 20 publications

References 21 publications

Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer

Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer

Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications

Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer

Contact Info

Product

Resources

About